|1.||Bear, Harry D: 8 articles (01/2014 - 01/2002)|
|2.||Graham, Laura: 5 articles (01/2011 - 09/2004)|
|3.||Manjili, Masoud H: 4 articles (11/2013 - 10/2009)|
|4.||Lang, Florian: 3 articles (01/2013 - 12/2003)|
|5.||Miller, Catriona H T: 3 articles (01/2010 - 09/2004)|
|6.||Strzadala, Leon: 3 articles (09/2005 - 03/2002)|
|7.||Chin, Cynthia S: 3 articles (09/2004 - 01/2002)|
|8.||Takeuchi, Shinji: 2 articles (03/2015 - 03/2012)|
|9.||Matsuda, Tadashi: 2 articles (03/2015 - 03/2012)|
|10.||Takahashi, Miki: 2 articles (03/2015 - 03/2012)|
08/01/2015 - "Stimulation with PMA/ionomycin led to indiscriminate expression in peripheral blood tumor cells and control T-cells. "
10/14/2014 - "Ionomycin stimulated GPEtn release from benign PNT2C2 cells but not from cancer-derived cell lines P4E6 or PC3. "
11/01/2011 - "Subsequently, over-expression of HMBOX1 significantly inhibited the expression and production of IFN-γ in NK cells in response to the stimulation of tumor cell K562 or PMA/ionomycin. "
07/01/2010 - "Regression of established tumors can be induced by adoptive immunotherapy (AIT) with tumor draining lymph node (DLN) lymphocytes activated with bryostatin and ionomycin (B/I). "
01/01/2010 - "Regression of established tumors can be induced by adoptive immunotherapy with tumor draining lymph node lymphocytes activated with bryostatin and ionomycin. "
|2.||Osteosarcoma (Osteogenic Sarcoma)
02/01/2014 - "Here we found that a 1-h hypoxic preconditioning delayed apoptosis and improved cell survival after stimulation with various apoptotic inducers including H2O2, ionomycin, and arachidonic acid in mitochondrial DNA T8993G mutation (NARP) osteosarcoma 143B cybrids, an F1F0-ATP synthase defect cell model. "
05/15/1991 - "Pretreatment of UMR-106 cells (rat osteoblast like osteosarcoma cell line) with calcium ionophores (A23187 or ionomycin) for 6h resulted in approximately 50% decrease of PTH-stimulated cAMP production. "
03/01/1986 - "To test this hypothesis directly, we measured the cytosolic free Ca2+ concentration ([Ca2+]i) in two hormone-responsive human (SaOS-2 and G-292) and two rat osteosarcoma cell lines (Ros 25/1 and Ros 17/2.8) and in primary cultures of bone cells from neonatal mouse calvaria using the fluorescent Ca2+ indicator Quin 2. Actions of bovine PTH-(1-34), vasoactive intestinal peptide, epidermal growth factor, prostaglandin E2, and ionomycin were studied. "
|4.||Body Weight (Weight, Body)
03/01/1997 - "To assess in vivo therapeutic efficacy, rats who had been inoculated intradermally with RT-2 cells three days earlier received an intravenous injection of RT-2- or D74-sensitized DLN cells (10(6) cells/gram body weight) expanded after activation with Bryostatin-1 and ionomycin or an equal number of lymphokine-activated killer (LAK) cells. "
05/01/2014 - "Thus, influence of ionomycin on human leukemia Jurkat T cell behaviors and its preliminary mechanistic process were explored in the presence of PDBu. "
01/20/2004 - "The constitutive CD137 expression on unstimulated T or B leukemia cells presents some differences compared to CD137 expressed on PMA/ionomycin-activated T leukemia cells. "
09/01/2002 - "Regulation of ionomycin-mediated granule release from rat basophil leukemia cells."
05/01/2014 - "These results indicate that ionomycin may strongly inhibit human acute T lymphocyte leukemia progress in the presence of PDBu through the inhibition of ERK1/2 signaling, the activation of caspase-3 and the attenuation of TGF-β mediated by the [Ca2(+)]i and pHi enhancement, providing a novel insight into function and potential application of both ionomycin and PDBu. "
02/01/2014 - "We investigated how EPA and DHA affect Th2 cytokine expression in phorbol 12-myristate 13-acetate- and ionomycin (PI)-activated RBL-2H3 basophilic leukemia cells. "
|2.||Arachidonic Acid (Vitamin F)
|4.||Mitochondrial DNA (mtDNA)